Atomo NewsGet the app

Get the latest Science News and Discoveries

EA5181 phase 3 trial finds no OS benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable stage 3 NSCLC - EurekAlert!


Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of Trial

Trial

Photo of EA5181

EA5181

Photo of consolidation

consolidation

Related news:

News photo

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer - EurekAlert!

News photo

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC - EurekAlert!

News photo

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC - EurekAlert!

« Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use? - EurekAlert!
Just like humans, many animals get more aggressive in the heat »